A novel signature based on CeRNA and immune status predicts prognostic risk and drug sensitivity in gastric cancer patients

Abstract

BackgroundAt present, there is increasing evidence that both competitive endogenous RNAs (ceRNAs) and immune status in the tumor microenvironment (TME) can affect the progression of gastric cancer (GC), and are closely related to the prognosis of patients. However, few studies have linked the two to jointly determine the prognosis of patients with GC. This study aimed to develop a combined prognostic model based on ceRNAs and immune biomarkers.MethodsFirst, the gene expression profiles and clinical information were downloaded from TCGA and GEO databases. Then two ceRNA networks were constructed on the basis of circRNA. Afterwards, the key genes were screened by univariate Cox regression analysis and Lasso regression analysis, and the ceRNA-related prognostic model was constructed by multivariate Cox regression analysis. Next, CIBERSORT and ESTIMATE algorithms were utilized to obtain the immune cell infiltration abundance and stromal/immune score in TME. Furthermore, the correlation between ceRNAs and immunity was found out through co-expression analysis, and another immune-related prognosis model was established. Finally, combining these two models, a comprehensive prognostic model was built and visualized with a nomogram.ResultsThe (circRNA, lncRNA)-miRNA-mRNA regulatory network of GC was constructed. The predictive power of ceRNA-related and immune-related prognosis models was moderate. Co-expression analysis showed that the ceRNA network was correlated with immunity. The integrated model of combined ceRNAs and immunity in the TCGA training set, the AUC values of 1, 3, and 5-year survival rates were 0.78, 0.76, and 0.78, respectively; in the independent external validation set GSE62254, they were 0.81, 0.79, and 0.78 respectively; in GSE15459, they were 0.84, 0.88 and 0.89 respectively. Besides, the prognostic score of the comprehensive model can predict chemotherapeutic drug resistance. Moreover, we found that plasma variant translocation 1 (PVT1) and infiltrating immune cells (mast cells) are worthy of further investigation as independent prognostic factors.ConclusionsTwo ceRNA regulatory networks were constructed based on circRNA. At the same time, a comprehensive prognosis model was established, which has a high clinical significance for prognosis prediction and chemotherapy drug selection of GC patients.

A disulfidptosis-related LncRNAs index predicting prognosis and tumor microenvironment in colorectal cancer

“…This emerging form cell death may play a positive role in tumor growth and treatment resistance. Recent studies have reported the value of disul dptosis-associated genes in bladder cancer, breast cancer, and lung cancer, such as identifying tumor subtypes associated with disul dptosis, constructing relevant prognostic models, and screening potential therapeutic targets [14][15][16] .…”

Bioinformatic analysis of differentially expressed profiles of lncRNAs and miRNAs with their related ceRNA network in endometrial cancer

“…[6] In recent years, lncRNA-miRNA-mRNA ceRNA regulatory networks have been identified in gastric cancer, lung cancer, liver cancer, and ovarian cancer and have been confirmed by various studies. [7][8][9] However, lncRNAs that perform ceRNA functions in EC are still poorly understood. Therefore, there is an urgent need to investigate lncRNA expression regulation networks based on the ceRNA hypothesis, which can provide a theoretical basis for the diagnosis and treatment of EC.…”

Identification of GNG7 as a novel biomarker and potential therapeutic target for gastric cancer via bioinformatic analysis and in vitro experiments

“…Stomach adenocarcinoma (STAD) remains the most common pathological type of GC, which originates from the normal gastric mucosal epithelium [2]. Owing to the nonspecific symptoms at early stages, most patients with GC are diagnosed at advanced stages, leading to the loss of optimal surgical treatment opportunity [3].…”

“…Stomach adenocarcinoma (STAD) remains the most common pathological type of GC, which originates from the normal gastric mucosal epithelium [ 2 ]. Owing to the nonspecific symptoms at early stages, most patients with GC are diagnosed at advanced stages, leading to the loss of optimal surgical treatment opportunity [ 3 ]. Traditional strategies employed in the treatment of GC include surgery, chemotherapy, radiotherapy, biotherapy, and others; however, their overall therapeutic effect is far from satisfactory.…”